WO2016029002A3 - Growth factor receptor inhibitors - Google Patents

Growth factor receptor inhibitors Download PDF

Info

Publication number
WO2016029002A3
WO2016029002A3 PCT/US2015/046089 US2015046089W WO2016029002A3 WO 2016029002 A3 WO2016029002 A3 WO 2016029002A3 US 2015046089 W US2015046089 W US 2015046089W WO 2016029002 A3 WO2016029002 A3 WO 2016029002A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
factor receptor
receptor inhibitors
formula
salt
Prior art date
Application number
PCT/US2015/046089
Other languages
French (fr)
Other versions
WO2016029002A2 (en
Inventor
Mei Lai
Andrew D. SIMMMONS
Sarah JAW-TSAI
Thomas Christian HARDING
Original Assignee
Clovis Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clovis Oncology, Inc. filed Critical Clovis Oncology, Inc.
Publication of WO2016029002A2 publication Critical patent/WO2016029002A2/en
Publication of WO2016029002A3 publication Critical patent/WO2016029002A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of formula (I) or salts thereof as IGF-1R/INSR inhibitors are provided. The compounds may be used in method of treating cancer. Pharmaceutical compositions containing a compound of formula (I) or a salt thereof and a pharmaceutical acceptable excipient are also provided, as are kits containing a compound of formula (I) or a salt thereof and instructions for use, e.g., in a method of treating cancer.
PCT/US2015/046089 2014-08-22 2015-08-20 Growth factor receptor inhibitors WO2016029002A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462040625P 2014-08-22 2014-08-22
US62/040,625 2014-08-22
US201462081300P 2014-11-18 2014-11-18
US62/081,300 2014-11-18

Publications (2)

Publication Number Publication Date
WO2016029002A2 WO2016029002A2 (en) 2016-02-25
WO2016029002A3 true WO2016029002A3 (en) 2016-04-14

Family

ID=55351379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/046089 WO2016029002A2 (en) 2014-08-22 2015-08-20 Growth factor receptor inhibitors

Country Status (1)

Country Link
WO (1) WO2016029002A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL245861A0 (en) 2016-05-25 2016-09-04 Yeda Res & Dev Use of agents for treating drug resistant tumors
CN106243044A (en) * 2016-06-30 2016-12-21 浙江大学 Pyridine derivatives containing halo acrylamide side chain and preparation and application
CN106831730B (en) * 2017-01-11 2019-11-26 温州医科大学 A kind of substituted diaminopyrimidines and its preparing the purposes in anti-malignant tumor medicine

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018141A1 (en) * 2007-06-12 2009-01-15 Robert Shoemaker Kinase inhibitors, compositions thereof, and methods of use therewith
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
US20110098280A1 (en) * 2003-08-15 2011-04-28 Novartis Ag 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US20110190271A1 (en) * 2003-08-07 2011-08-04 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents
US20110201606A1 (en) * 2003-03-14 2011-08-18 Novartis Ag Pyrimidine derivatives
US20130190320A1 (en) * 2012-01-13 2013-07-25 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents
US20130267530A1 (en) * 2012-03-15 2013-10-10 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
WO2014123476A1 (en) * 2013-02-05 2014-08-14 Stenman Göran Improved treatment for adenoid cystic carcinoma

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110201606A1 (en) * 2003-03-14 2011-08-18 Novartis Ag Pyrimidine derivatives
US20110190271A1 (en) * 2003-08-07 2011-08-04 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents
US20110098280A1 (en) * 2003-08-15 2011-04-28 Novartis Ag 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US20090018141A1 (en) * 2007-06-12 2009-01-15 Robert Shoemaker Kinase inhibitors, compositions thereof, and methods of use therewith
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
US20130190320A1 (en) * 2012-01-13 2013-07-25 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents
US20130267530A1 (en) * 2012-03-15 2013-10-10 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
WO2014123476A1 (en) * 2013-02-05 2014-08-14 Stenman Göran Improved treatment for adenoid cystic carcinoma

Also Published As

Publication number Publication date
WO2016029002A2 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
WO2014105958A3 (en) Fused pyrimidine compounds and use thereof
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
MA39986A (en) Purine derivatives as cd73 inhibitors for the treatment of cancer
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
CN106536480A8 (en) The derovatives of pyrrolidines 2,5, pharmaceutical composition and the method as IDO1 inhibitor
UA117976C2 (en) Aminopyrimidinyl compounds as jak inhibitors
EA201692095A1 (en) IMIDAZO [4,5-C] QUINOLIN-2-NEW COMPOUNDS AND THEIR APPLICATION IN CANCER TREATMENT
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
PH12016500169A1 (en) Polymorph of syk inhibitors
MD4820C1 (en) Substituted dihydroisoquinolinone compounds
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
TW201613864A (en) Novel compounds
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2016183120A8 (en) Inhibitors of influenza viruses replication
WO2016029002A3 (en) Growth factor receptor inhibitors
WO2016164295A3 (en) Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors
WO2017095950A3 (en) Compounds for treating proliferative diseases
SG11201903463PA (en) Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same
MX2015012600A (en) Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl) methanone compounds as cancer cell growth inhibitors.
MX2019005723A (en) Fgfr4 inhibitor and preparation method and use thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15833065

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15833065

Country of ref document: EP

Kind code of ref document: A2